Keros Therapeutics Inc

KROSNASDAQ · USD
11.20USD-0.32 (-2.78%)
915

Keros Therapeutics Inc (KROS) Straddle

KROS straddle scan found 5 qualifying long straddle setups on the previous trading day. Probability of profit reaches up to 57.1%.

Read more

Trading a KROS straddle lets you take a pure volatility position on Keros Therapeutics Inc without committing to a direction. Keros Therapeutics Inc's straddle involves buying (or selling) a call and a put at the same strike and expiration, profiting when the stock moves more (or less) than the combined premium implies. Use our scanner to evaluate KROS straddle pricing in real time and find the moments when expected moves are mispriced.

A long straddle on KROS profits from large moves in either direction and is a classic play into binary events like earnings, product announcements, or macro releases. A short straddle profits when Keros Therapeutics Inc stays range-bound and implied volatility contracts. The breakeven points are simple: strike plus total premium on the upside, strike minus total premium on the downside. Comparing the KROS straddle price to historical realized moves helps you judge whether the market is overpaying or underpaying for volatility.

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, and is currently in Phase 1 clinical trial; and KER-012, which is in Phase 1 clinical trial to treat disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension.

The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

Earnings, product cycles, macro prints — any time volatility itself is the trade, the KROS straddle is the cleanest expression of that view. Our scanner prices every KROS straddle against historical realized moves, flags expirations where the market is overpaying or underpaying for vol, and ranks setups by breakeven width and IV rank. Whether you're long a KROS straddle into a catalyst or short a KROS straddle to harvest decay, the options straddle setups that matter are all in one place.

Mar 19, 202712.50$5.3517150%57.1%$17.85$7.150
Oct 16, 202612.50$2.151750%52.2%$14.65$10.350
Nov 20, 202610.00$2.835250%49.3%$12.83$7.180
Dec 18, 202612.50$5.188050%41.2%$17.68$7.333
Nov 20, 202612.50$5.255250%29.5%$17.75$7.250

As of October 5, 2026

Find the right straddle before volatility moves

Track KROS straddle pricing across expirations, filter by IV rank and breakeven points, and build a setup that fits your view before the move happens.

Start your 14-day free trial